Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for hepatic ascites in decompensated liver cirrhosis
PACTR202402866059449Phase 4Not yet recruiting
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in ascites and Cirrhosis (2 arms), sponsored by None. Primary endpoints: Efficacy of empagliflozin in management of hepatic ascites and Safety of empagliflozin. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
ascitesCirrhosis
Beyond the preview
Go deeper on PACTR202402866059449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402866059449.